PanOptica, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2009-01-01
- Employees
- 101
- Market Cap
- -
Clinical Trials
7
Active:4
Completed:3
Trial Phases
1 Phases
Phase 1:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (100.0%)Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD
Phase 1
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: PAN-90806 Ophthalmic Suspension
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- PanOptica, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT03479372
- Locations
- 🇺🇸
Colorado Retina Associates, Golden, Colorado, United States
🇺🇸Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
🇺🇸Retinal Consultants of Nevada, Las Vegas, Nevada, United States
Study of Topical Ocular PAN-90806 in PDR
Phase 1
Completed
- Conditions
- Diabetic Retinopathy
- Interventions
- Drug: PAN-90806 Ophthalmic Solution
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- PanOptica, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02475109
- Locations
- 🇺🇸
Valley Retina Institute, McAllen, Texas, United States
Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
Phase 1
Completed
- Conditions
- Age-Related Macular Degeneration (AMD)
- Interventions
- Drug: PAN-90806 Ophthalmic Solution
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- PanOptica, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02022540
News
No news found